Head-To-Head Comparison: Alpha Cognition (ACOG) versus Its Peers

Alpha Cognition (NASDAQ:ACOG) is one of 300 public companies in the “Biological products, except diagnostic” industry, but how does it compare to its peers? We will compare Alpha Cognition to related businesses based on the strength of its institutional ownership, dividends, valuation, earnings, analyst recommendations, profitability and risk.

Earnings and Valuation

This table compares Alpha Cognition and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Alpha Cognition	N/A	-$13.77 million	-2.16
Alpha Cognition Competitors	$574.62 million	-$70.96 million	-0.15

Alpha Cognition’s peers have higher revenue, but lower earnings than Alpha Cognition. Alpha Cognition is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

50.4% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 31.5% of Alpha Cognition shares are held by insiders. Comparatively, 15.7% of shares of all “Biological products, except diagnostic” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Alpha Cognition and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	N/A	N/A	-344.17%
Alpha Cognition Competitors	-2,185.76%	-161.46%	-40.62%

Analyst Ratings

This is a summary of recent recommendations and price targets for Alpha Cognition and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0	0	1	0	3.00
Alpha Cognition Competitors	1924	5381	13923	296	2.58

Alpha Cognition currently has a consensus target price of $20.00, indicating a potential upside of 261.66%. As a group, “Biological products, except diagnostic” companies have a potential upside of 103.08%. Given Alpha Cognition’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Alpha Cognition is more favorable than its peers.

Risk and Volatility

Alpha Cognition has a beta of 2.5, suggesting that its share price is 150% more volatile than the S&P 500. Comparatively, Alpha Cognition’s peers have a beta of -3.86, suggesting that their average share price is 486% less volatile than the S&P 500.

Summary

Alpha Cognition beats its peers on 8 of the 13 factors compared.

Alpha Cognition Company Profile

Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.